» Articles » PMID: 32606948

Prospective Study of the Clinical Impact of Epithelial and Mesenchymal Circulating Tumor Cells in Localized Prostate Cancer

Overview
Publisher Dove Medical Press
Specialty Oncology
Date 2020 Jul 2
PMID 32606948
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Although circulating tumor cells (CTCs) are considered as a surrogate marker in monitoring disease progression and treatment response in late stage prostate cancer (PCa), its clinical impact in localized PCa remains unclear, indicating the limitation that is simply based on cell count. This perspective observational study aimed to detect the epithelial-to-mesenchymal transition (EMT) subtypes of CTCs in localized PCa and analyze their clinical relevance and application in predicting PCa stages before surgery compared with the Partin table.

Patients And Methods: Between August 2017 and April 2019, 80 newly diagnosed localized PCa patients were enrolled in the study. Peripheral blood samples (5 mL) were collected prior to surgery. The CanPatrol CTC enrichment technique, a size-based isolation method, was used to detect the EMT CTCs. Clinical relevance of the CTCs was analyzed with Spearman's rank correlation test. Models to predict pathological were built with multivariate logistic regression. Receiver operating characteristic (ROC) curve and area under the curve (AUC) analysis were performed to evaluate the accuracy of the prediction model.

Results: CTCs were detected in 55% of all patients. The biophenotypic CTCs were most valuable and closely correlated with PSA, Gleason score, D'Amico risk classification, and pathological stage in localized PCa. The mesenchymal subtype was rare in this population but associated with seminal vesicle invasion, while the epithelial subtype had limited clinical significance. In addition, the biophenotypic CTCs combined with traditional clinical variables were analyzed by multivariate logistic regression to predict organ-confined disease before surgery, of which the AUC reached 0.818 and was superior to the Partin table 2017 in our cohort.

Conclusion: This study highlights the clinical impact of the biophenotypic CTCs in localized PCa, which was most closely related to clinical variables and could help to predict pathology outcomes before surgery.

Citing Articles

Detection of circulating tumor cells in non-metastatic prostate cancer through integration of a microfluidic CTC enrichment system and multiparametric flow cytometry.

Kilercik M, Ozgur E, Sahin S, Sen Dogan B, Mutlu E, Cihan C PLoS One. 2024; 19(10):e0312296.

PMID: 39441869 PMC: 11498670. DOI: 10.1371/journal.pone.0312296.


Protocol for a prospective study evaluating circulating tumour cells status to predict radical prostatectomy treatment failure in localised prostate cancer patients (C-ProMeta-1).

Al-Hammouri T, Almeida-Magana R, Lawrence R, Duffy T, White L, Burke E BMC Cancer. 2023; 23(1):581.

PMID: 37353740 PMC: 10288675. DOI: 10.1186/s12885-023-11081-0.


A Systematic Review of Circulating Tumor Cells Clinical Application in Prostate Cancer Diagnosis.

Enikeev D, Morozov A, Babaevskaya D, Bazarkin A, Malavaud B Cancers (Basel). 2022; 14(15).

PMID: 35954464 PMC: 9367494. DOI: 10.3390/cancers14153802.


Predictive Value of Circulating Tumor Cells Detected by ISET in Patients with Non-Metastatic Prostate Cancer Undergoing Radical Prostatectomy.

Garrido Castillo L, Mejean A, Vielh P, Anract J, Decina A, Nalpas B Life (Basel). 2022; 12(2).

PMID: 35207452 PMC: 8877346. DOI: 10.3390/life12020165.


Circulating tumor cells: biology and clinical significance.

Lin D, Shen L, Luo M, Zhang K, Li J, Yang Q Signal Transduct Target Ther. 2021; 6(1):404.

PMID: 34803167 PMC: 8606574. DOI: 10.1038/s41392-021-00817-8.

References
1.
Tsumura H, Satoh T, Ishiyama H, Tabata K, Takenaka K, Sekiguchi A . Perioperative Search for Circulating Tumor Cells in Patients Undergoing Prostate Brachytherapy for Clinically Nonmetastatic Prostate Cancer. Int J Mol Sci. 2017; 18(1). PMC: 5297762. DOI: 10.3390/ijms18010128. View

2.
Pantel K, Hille C, Scher H . Circulating Tumor Cells in Prostate Cancer: From Discovery to Clinical Utility. Clin Chem. 2019; 65(1):87-99. DOI: 10.1373/clinchem.2018.287102. View

3.
Jolly M, Tripathi S, Jia D, Mooney S, Celiktas M, Hanash S . Stability of the hybrid epithelial/mesenchymal phenotype. Oncotarget. 2016; 7(19):27067-84. PMC: 5053633. DOI: 10.18632/oncotarget.8166. View

4.
Jin X, Zhu L, Qian K, Feng Y, Zhou J, Wang R . Circulating tumor cells in early stage lung adenocarcinoma: a case series report and literature review. Oncotarget. 2017; 8(14):23130-23141. PMC: 5410291. DOI: 10.18632/oncotarget.15506. View

5.
Gorges T, Tinhofer I, Drosch M, Rose L, Zollner T, Krahn T . Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition. BMC Cancer. 2012; 12:178. PMC: 3502112. DOI: 10.1186/1471-2407-12-178. View